Organigram Holdings Inc. (NASDAQ:OGI - Free Report) - Research analysts at Alliance Global Partners lowered their Q1 2025 EPS estimates for shares of Organigram in a report released on Wednesday, December 18th. Alliance Global Partners analyst A. Grey now expects that the company will post earnings of ($0.04) per share for the quarter, down from their prior forecast of ($0.01). The consensus estimate for Organigram's current full-year earnings is ($0.20) per share. Alliance Global Partners also issued estimates for Organigram's Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.11) EPS and FY2026 earnings at ($0.08) EPS.
NASDAQ OGI opened at $1.56 on Monday. The business's fifty day moving average is $1.61 and its 200-day moving average is $1.67. The stock has a market capitalization of $196.80 million, a price-to-earnings ratio of -3.71 and a beta of 1.02. Organigram has a one year low of $1.21 and a one year high of $2.91.
Organigram (NASDAQ:OGI - Get Free Report) last released its earnings results on Wednesday, December 18th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Organigram had a negative net margin of 45.57% and a negative return on equity of 16.76%.
Several institutional investors have recently bought and sold shares of OGI. Toronto Dominion Bank boosted its position in Organigram by 803.7% during the third quarter. Toronto Dominion Bank now owns 16,727 shares of the company's stock worth $30,000 after purchasing an additional 14,876 shares during the period. Renaissance Technologies LLC raised its holdings in Organigram by 40.8% during the 2nd quarter. Renaissance Technologies LLC now owns 816,948 shares of the company's stock valued at $1,258,000 after acquiring an additional 236,700 shares during the period. AdvisorShares Investments LLC lifted its position in shares of Organigram by 11.8% during the second quarter. AdvisorShares Investments LLC now owns 1,000,126 shares of the company's stock worth $1,540,000 after acquiring an additional 105,468 shares in the last quarter. Finally, Tidal Investments LLC lifted its position in shares of Organigram by 8.3% during the third quarter. Tidal Investments LLC now owns 1,948,188 shares of the company's stock worth $3,526,000 after acquiring an additional 149,171 shares in the last quarter. Hedge funds and other institutional investors own 34.63% of the company's stock.
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.